FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048333079> ?p ?o ?g. }

• W3048333079 abstract "Psoriasis is a chronic inflammatory disease associated with comorbidities known to increase risk of severe COVID-19, such as hypertension, cardiovascular disease, diabetes and obesity.1, 2 Use of systemic therapies may increase a patient’s risk of infections.3 Our study aims to evaluate the association of psoriasis systemic therapy and COVID outcomes. This retrospective cohort study used RPDR, a clinical data registry, to identify patients with psoriasis (ICD-10 code L40) and positive COVID RT-PCR, between March and May/2020. By reviewing medical records on EPIC, active psoriasis prior to COVID was confirmed. The exposure was psoriasis systemic therapy for at least three months prior to COVID. Our primary outcome was a composite of ICU admission, intubation and/or death. Logistic regression assessed the association of therapy status with COVID-19 severe composite outcome (SCO). We adjusted for age and diabetes, based on prior knowledge. In addition, given the small number of outcomes, we used a propensity score (PS), calculated as a predicted probability of receiving or not systemic treatment as a function of all clinically relevant variables. The effect of systemic treatment was adjusted using this PS as covariate in another model (SPSS 20.2, IBM, USA). Our study included 104 patients. Among 37 patients on systemic therapy, 27 patients were using biologics (18, on anti-TNFα; 4, on anti-IL17; 3, on anti-IL12/23; and 2, on anti-IL23). There were 13 patients on methotrexate (10 to 22.5 mg/week). Three patients were taking both. Most comorbidities and demographics were similar between groups. Analysing patients on methotrexate and biologics separately did not show differences (Table 1). There were no significant differences in the SCO or other outcomes between patients taking or not systemic therapies. 8.3% of patients on biologics, 20% of patients on methotrexate and 16.4% of patients not on systemic therapy had the SCO. Older patients and the presence of diabetes mellitus, hypertension, cardiovascular and renal disease significantly increased the OR of developing the SCO (Table 2). Adjusting for age and diabetes, systemic therapy remained not associated with our main outcome (OR 0.82, 0.21–3.24, P = 0.77). In another model, all covariates became balanced between exposure groups after adjusting for the PS and systemic treatment remained not associated with the SCO (OR 0.91, 0.17–4.81, P = 0.92). Amidst this pandemic, dermatologists have to decide whether holding psoriasis therapies may protect patients or trigger a ‘cytokine storm’.4 In our study, we did not find increased rates of severe COVID in patients receiving systemic therapy. Prior studies have not shown worsen COVID-19 outcomes among psoriasis patients on biologics.5-7 A large Italian study did not detect ICU admissions or deaths suspected for COVID-19.8 Few studies evaluated conventional systemic therapies. One study reported no deaths or hospitalizations in patients using cyclosporine.9 Methotrexate was associated with more hospitalizations in one study.10 In our study, methotrexate did not significantly increase severe outcomes. In our cohort, by requiring confirmation of COVID by PCR testing, patients with more severe infection may have been included and 15 patients were admitted to an ICU, intubated and/or died. However, these proportions were similar in both exposure groups. As expected, increased age, diabetes, hypertension, cardiovascular and renal diseases increased the odds of SCO. As a result of real-world data, patients with increased number of comorbidities may have decreased likelihood of receiving systemic therapy for psoriasis. As an attempt to circumvent that, we used PS analysis, comparing patients with similar chance of allocation in the exposure groups. Detection of COVID-confirmed severe outcomes in psoriasis population and detailed information on significant covariates allowed evaluation of crude and adjusted effect of systemic therapy. Our study suggests that systemic psoriasis therapy does not worsen COVID-19. Larger detailed studies are needed. Patients in this manuscript have given written informed consent to publication of their case details. Dr. Lima serves on the speakers’ bureau for Abbvie. Mary Cueva has no relevant conflicts of interest. Dr. Lopes receives scholarship from CAPES - Brazilian Federal Agency for Support and Evoluation of Graduate Education within the Ministry of Education of Brazil. Dr. Alora has been an investigator for Abbvie, Janssen, Celgene, Eli Lilly, Pfizer, Inc., Novartis. None." @default.
• W3048333079 created "2020-08-13" @default.
• W3048333079 creator A5008515337 @default.
• W3048333079 creator A5028533771 @default.
• W3048333079 creator A5082000323 @default.
• W3048333079 creator A5087905862 @default.
• W3048333079 date "2020-09-11" @default.
• W3048333079 modified "2023-09-27" @default.
• W3048333079 title "Severe COVID‐19 outcomes in patients with psoriasis" @default.
• W3048333079 cites W2068419991 @default.
• W3048333079 cites W2912058252 @default.
• W3048333079 cites W3009885589 @default.
• W3048333079 cites W3012932999 @default.
• W3048333079 cites W3015495837 @default.
• W3048333079 cites W3018029174 @default.
• W3048333079 cites W3020611303 @default.
• W3048333079 cites W3020694641 @default.
• W3048333079 cites W3020883613 @default.
• W3048333079 cites W3029872711 @default.
• W3048333079 doi "https://doi.org/10.1111/jdv.16867" @default.
• W3048333079 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7436403" @default.
• W3048333079 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32780905" @default.
• W3048333079 hasPublicationYear "2020" @default.
• W3048333079 type Work @default.
• W3048333079 sameAs 3048333079 @default.
• W3048333079 citedByCount "13" @default.
• W3048333079 countsByYear W30483330792020 @default.
• W3048333079 countsByYear W30483330792021 @default.
• W3048333079 countsByYear W30483330792022 @default.
• W3048333079 crossrefType "journal-article" @default.
• W3048333079 hasAuthorship W3048333079A5008515337 @default.
• W3048333079 hasAuthorship W3048333079A5028533771 @default.
• W3048333079 hasAuthorship W3048333079A5082000323 @default.
• W3048333079 hasAuthorship W3048333079A5087905862 @default.
• W3048333079 hasBestOaLocation W30483330791 @default.
• W3048333079 hasConcept C121608353 @default.
• W3048333079 hasConcept C126322002 @default.
• W3048333079 hasConcept C134018914 @default.
• W3048333079 hasConcept C151956035 @default.
• W3048333079 hasConcept C16005928 @default.
• W3048333079 hasConcept C167135981 @default.
• W3048333079 hasConcept C185926286 @default.
• W3048333079 hasConcept C195910791 @default.
• W3048333079 hasConcept C2776252253 @default.
• W3048333079 hasConcept C2776914184 @default.
• W3048333079 hasConcept C2779159551 @default.
• W3048333079 hasConcept C2780564577 @default.
• W3048333079 hasConcept C530470458 @default.
• W3048333079 hasConcept C555293320 @default.
• W3048333079 hasConcept C71924100 @default.
• W3048333079 hasConceptScore W3048333079C121608353 @default.
• W3048333079 hasConceptScore W3048333079C126322002 @default.
• W3048333079 hasConceptScore W3048333079C134018914 @default.
• W3048333079 hasConceptScore W3048333079C151956035 @default.
• W3048333079 hasConceptScore W3048333079C16005928 @default.
• W3048333079 hasConceptScore W3048333079C167135981 @default.
• W3048333079 hasConceptScore W3048333079C185926286 @default.
• W3048333079 hasConceptScore W3048333079C195910791 @default.
• W3048333079 hasConceptScore W3048333079C2776252253 @default.
• W3048333079 hasConceptScore W3048333079C2776914184 @default.
• W3048333079 hasConceptScore W3048333079C2779159551 @default.
• W3048333079 hasConceptScore W3048333079C2780564577 @default.
• W3048333079 hasConceptScore W3048333079C530470458 @default.
• W3048333079 hasConceptScore W3048333079C555293320 @default.
• W3048333079 hasConceptScore W3048333079C71924100 @default.
• W3048333079 hasIssue "12" @default.
• W3048333079 hasLocation W30483330791 @default.
• W3048333079 hasLocation W30483330792 @default.
• W3048333079 hasLocation W30483330793 @default.
• W3048333079 hasOpenAccess W3048333079 @default.
• W3048333079 hasPrimaryLocation W30483330791 @default.
• W3048333079 hasRelatedWork W1488789440 @default.
• W3048333079 hasRelatedWork W1698752670 @default.
• W3048333079 hasRelatedWork W1991438449 @default.
• W3048333079 hasRelatedWork W2004721589 @default.
• W3048333079 hasRelatedWork W2050278325 @default.
• W3048333079 hasRelatedWork W2072904485 @default.
• W3048333079 hasRelatedWork W2795583931 @default.
• W3048333079 hasRelatedWork W3097089672 @default.
• W3048333079 hasRelatedWork W3153421255 @default.
• W3048333079 hasRelatedWork W4224231443 @default.
• W3048333079 hasVolume "34" @default.
• W3048333079 isParatext "false" @default.
• W3048333079 isRetracted "false" @default.
• W3048333079 magId "3048333079" @default.
• W3048333079 workType "article" @default.